Cumberland Pharmaceuticals Inc. CPIX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
54/100
Moderate

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the … Full CPIX analysis →

Competitive advantage assessment

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.80), demonstrating pricing resilience across cycles.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.73), suggesting sticky customer base.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.13), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
54

Where CPIX ranks in Drug Manufacturers - Specialty & Generic

Cumberland Pharmaceuticals Inc. ranks #32 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 35%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near CPIX in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
28 Alvotech ALVO 56/100 Moderate
29 Alvotech Warrant ALVOW 56/100 Moderate
30 Supernus Pharmaceuticals, Inc. SUPN 55/100 Moderate
31 Anika Therapeutics Inc. ANIK 54/100 Moderate
32 Cumberland Pharmaceuticals Inc. CPIX 54/100 Moderate
33 Dynavax Technologies Corporatio DVAX 52/100 Moderate
34 HUTCHMED (China) Limited HCM 51/100 Moderate
35 Esperion Therapeutics, Inc. ESPR 50/100 Developing
36 Rockwell Medical, Inc. RMTI 47/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How CPIX scores on the Corporate Default defenses

Pricing Power

Score 54 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 42 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 71 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 45 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 48 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 63 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CPIX's moat

What is Cumberland Pharmaceuticals Inc.'s moat score?

Cumberland Pharmaceuticals Inc. (CPIX) scores 54 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #32 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 35%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Customer Stickiness (71/100) and its weakest is Cost Advantage (42/100).

How does Cumberland Pharmaceuticals Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Cumberland Pharmaceuticals Inc. ranks #32 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Anika Therapeutics Inc. (ANIK) at 54 just above it and Dynavax Technologies Corporatio (DVAX) at 52 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Cumberland Pharmaceuticals Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Cumberland Pharmaceuticals Inc.?

The Corporate Default template measures 6 defenses, and CPIX scores: Pricing Power (54), Cost Advantage (42), Customer Stickiness (71), Capital Efficiency (45), Resilience (48), Scale & Market Position (63). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000